LONDON - Therapeutic Antibodies Inc. (TAb) has submitted a product license application to the FDA for its CroTAb antivenom product.

CroTAb, which has been granted orphan drug status, is a polyclonal antibody designed to neutralize the effects of bites from North American pit vipers. TAb, headquartered in Nashville but based in London, said 8,000 people a year are treated for such bites in the U.S.

The application triggers a milestone payment from Altana Inc., of Melville, N.Y., which is a subsidiary of Byk Gulden, of Konstanz, Germany, and which has the U.S. rights to market CroTAb and other TAb emergency medicine products. - Nuala Moran

No Comments